High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma
Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas...
Gespeichert in:
Veröffentlicht in: | Journal of healthcare engineering 2022-02, Vol.2022, p.3565676-12 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 12 |
---|---|
container_issue | |
container_start_page | 3565676 |
container_title | Journal of healthcare engineering |
container_volume | 2022 |
creator | Tao, Ke Wei, Zhouxia Xia, Yan Zhao, Ruihong Xu, Hong |
description | Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA. |
doi_str_mv | 10.1155/2022/3565676 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8865998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2634512036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</originalsourceid><addsrcrecordid>eNp9kU1vGyEQhlHVqonS3HquOFZqnbCwwHKpFFlOYylSrX6c0Zid9VLtggvr5uPXl8RO1F7KhQEePTPoJeRtxc6qSspzzjg_F1JJpdULcsxZzWZcMPPyqeZGHpHTnH-ysoQRdSVekyMhOedNI47J_ZXf9PTb8uvqgi5utwlz9jHQVcLWuynTVYypnOImxOwzhdDSeUwJB5gw0xs_9XQ5jruAdBk6P0zp8d4XA0wew3RgFjlue9ggDHQOyfkQR3hDXnUwZDw97Cfkx-Xi-_xqdv3l83J-cT1zNWfTjDMNa2UUYmsa3joDqtOtqDoNWCE0GtGVL6-NERoFdqXWDa9Bas3QSSdOyKe9d7tbj9i6MlWCwW6THyHd2Qje_vsSfG838bdtGiWNaYrg_UGQ4q8d5smOPjscBggYd9lyJWpZcSZUQT_uUZdizgm75zYVsw-J2YfE7CGxgr_7e7Rn-CmfAnzYA70PLdz4_-v-AMrJoCA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634512036</pqid></control><display><type>article</type><title>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Tao, Ke ; Wei, Zhouxia ; Xia, Yan ; Zhao, Ruihong ; Xu, Hong</creator><contributor>Jain, Deepak Kumar</contributor><creatorcontrib>Tao, Ke ; Wei, Zhouxia ; Xia, Yan ; Zhao, Ruihong ; Xu, Hong ; Jain, Deepak Kumar</creatorcontrib><description>Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA.</description><identifier>ISSN: 2040-2295</identifier><identifier>EISSN: 2040-2309</identifier><identifier>DOI: 10.1155/2022/3565676</identifier><identifier>PMID: 35222883</identifier><language>eng</language><publisher>England: Hindawi</publisher><subject>Antigens, Differentiation ; Carcinoma ; Esophageal Neoplasms ; Humans ; Prognosis ; Receptors, Immunologic</subject><ispartof>Journal of healthcare engineering, 2022-02, Vol.2022, p.3565676-12</ispartof><rights>Copyright © 2022 Ke Tao et al.</rights><rights>Copyright © 2022 Ke Tao et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</citedby><cites>FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</cites><orcidid>0000-0003-2798-2078</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865998/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865998/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35222883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Jain, Deepak Kumar</contributor><creatorcontrib>Tao, Ke</creatorcontrib><creatorcontrib>Wei, Zhouxia</creatorcontrib><creatorcontrib>Xia, Yan</creatorcontrib><creatorcontrib>Zhao, Ruihong</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><title>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</title><title>Journal of healthcare engineering</title><addtitle>J Healthc Eng</addtitle><description>Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA.</description><subject>Antigens, Differentiation</subject><subject>Carcinoma</subject><subject>Esophageal Neoplasms</subject><subject>Humans</subject><subject>Prognosis</subject><subject>Receptors, Immunologic</subject><issn>2040-2295</issn><issn>2040-2309</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU1vGyEQhlHVqonS3HquOFZqnbCwwHKpFFlOYylSrX6c0Zid9VLtggvr5uPXl8RO1F7KhQEePTPoJeRtxc6qSspzzjg_F1JJpdULcsxZzWZcMPPyqeZGHpHTnH-ysoQRdSVekyMhOedNI47J_ZXf9PTb8uvqgi5utwlz9jHQVcLWuynTVYypnOImxOwzhdDSeUwJB5gw0xs_9XQ5jruAdBk6P0zp8d4XA0wew3RgFjlue9ggDHQOyfkQR3hDXnUwZDw97Cfkx-Xi-_xqdv3l83J-cT1zNWfTjDMNa2UUYmsa3joDqtOtqDoNWCE0GtGVL6-NERoFdqXWDa9Bas3QSSdOyKe9d7tbj9i6MlWCwW6THyHd2Qje_vsSfG838bdtGiWNaYrg_UGQ4q8d5smOPjscBggYd9lyJWpZcSZUQT_uUZdizgm75zYVsw-J2YfE7CGxgr_7e7Rn-CmfAnzYA70PLdz4_-v-AMrJoCA</recordid><startdate>20220216</startdate><enddate>20220216</enddate><creator>Tao, Ke</creator><creator>Wei, Zhouxia</creator><creator>Xia, Yan</creator><creator>Zhao, Ruihong</creator><creator>Xu, Hong</creator><general>Hindawi</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2798-2078</orcidid></search><sort><creationdate>20220216</creationdate><title>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</title><author>Tao, Ke ; Wei, Zhouxia ; Xia, Yan ; Zhao, Ruihong ; Xu, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens, Differentiation</topic><topic>Carcinoma</topic><topic>Esophageal Neoplasms</topic><topic>Humans</topic><topic>Prognosis</topic><topic>Receptors, Immunologic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tao, Ke</creatorcontrib><creatorcontrib>Wei, Zhouxia</creatorcontrib><creatorcontrib>Xia, Yan</creatorcontrib><creatorcontrib>Zhao, Ruihong</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of healthcare engineering</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tao, Ke</au><au>Wei, Zhouxia</au><au>Xia, Yan</au><au>Zhao, Ruihong</au><au>Xu, Hong</au><au>Jain, Deepak Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</atitle><jtitle>Journal of healthcare engineering</jtitle><addtitle>J Healthc Eng</addtitle><date>2022-02-16</date><risdate>2022</risdate><volume>2022</volume><spage>3565676</spage><epage>12</epage><pages>3565676-12</pages><issn>2040-2295</issn><eissn>2040-2309</eissn><abstract>Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA.</abstract><cop>England</cop><pub>Hindawi</pub><pmid>35222883</pmid><doi>10.1155/2022/3565676</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2798-2078</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2040-2295 |
ispartof | Journal of healthcare engineering, 2022-02, Vol.2022, p.3565676-12 |
issn | 2040-2295 2040-2309 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8865998 |
source | MEDLINE; Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
subjects | Antigens, Differentiation Carcinoma Esophageal Neoplasms Humans Prognosis Receptors, Immunologic |
title | High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T14%3A10%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20SIRPA%20Expression%20Predicts%20Poor%20Prognosis%20and%20Correlates%20with%20Immune%20Infiltrates%20in%20Patients%20with%20Esophageal%20Carcinoma&rft.jtitle=Journal%20of%20healthcare%20engineering&rft.au=Tao,%20Ke&rft.date=2022-02-16&rft.volume=2022&rft.spage=3565676&rft.epage=12&rft.pages=3565676-12&rft.issn=2040-2295&rft.eissn=2040-2309&rft_id=info:doi/10.1155/2022/3565676&rft_dat=%3Cproquest_pubme%3E2634512036%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634512036&rft_id=info:pmid/35222883&rfr_iscdi=true |